About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker OPK · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Aug 27, 2026Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants
NCT07512427 · MASH
OPK-88006, Placebo
OPK
OPKO Health, Inc.
Phase 1/2Recruiting30Dec 2027Registry ↗
Aug 20, 2026Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release…
NCT07494045 · CKD Stage 3, CKD Stage 4
CTAP101
OPK
OPKO Health, Inc.
Phase 2Recruiting40Oct 2027Registry ↗
Apr 3, 2026Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI
NCT03602261 · Secondary Hyperparathyroidism Due to Renal Causes, Chronic…
Calcifediol Oral Capsule, Placebo oral capsule
OPK
OPKO Health, Inc.
Phase 2Terminated44Feb 24, 2021Registry ↗
Jul 25, 2025Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary H…
NCT05543928 · Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
CTAP101, Placebo
OPK
OPKO Health, Inc.
Phase 3Terminated2Jun 19, 2024Registry ↗
Jul 20, 2025Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
NCT02968004 · Pediatric Growth Hormone Deficiency
MOD-4023, Somatropin
OPK
OPKO Health, Inc.
Phase 3Completed224Aug 2019Registry ↗
Apr 9, 2025Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
NCT02500316 · Growth Hormone Deficiency (GHD)
MOD-4023
OPK
OPKO Health, Inc.
Phase 2Completed48Nov 2023Registry ↗
May 28, 2024Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19
NCT04551911 · COVID-19, Coronavirus
Rayaldee, Placebo
OPK
OPKO Health, Inc.
Phase 2Completed171Oct 8, 2021Registry ↗
Dec 9, 2022Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release C…
NCT03588884 · Secondary Hyperparathyroidism Due to Renal Causes, Vitamin…
Calcifediol Oral Capsule, Calcifediol Oral Product
OPK
OPKO Health, Inc.
Phase 4Completed69Apr 24, 2020Registry ↗
Aug 12, 2022A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth…
NCT01909479 · Adult Growth Hormone Deficiency
MOD-4023, Placebo
OPK
OPKO Health, Inc.
Phase 3Terminated202Aug 2016Registry ↗
Sep 16, 2021Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasi…
NCT03297398 · Benign Prostatic Hyperplasia
Group-1 (15mg, OPK-88004), Group-2 (25 mg,OPK-88004)
OPK
OPKO Health, Inc.
Phase 2Terminated114Apr 18, 2019Registry ↗
Aug 12, 2021Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency
NCT03874013 · Growth Hormone Deficiency
MOD-4023, Genotropin
OPK
OPKO Health, Inc.
Phase 3Completed44Mar 6, 2020Registry ↗
Jun 15, 2021Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects
NCT03406377 · Type 2 Diabetes Mellitus
OPK-88003, Placebo
OPK
OPKO Health, Inc.
Phase 2Completed113Mar 8, 2019Registry ↗
May 27, 2021A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants
NCT02188303 · Healthy Volunteers
LY2944876, Placebo
OPK
OPKO Health, Inc.
Phase 1Terminated48Dec 2014Registry ↗
May 27, 2021A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available f…
NCT02119819 · Diabetes Mellitus, Type 2
LY2944876, Exenatide extended-release
OPK
OPKO Health, Inc.
Phase 2Completed420Aug 2015Registry ↗
May 20, 2021A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B
NCT02418793 · Hemophilia A, Hemophilia B
MOD-5014
OPK
OPKO Health, Inc.
Phase 1Completed27Sep 2018Registry ↗
Mar 23, 2021Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye Patients
NCT04063644 · Dry Eye Syndromes, Cataract
Vis Glyc Neo, Physiological saline solution
OPK
OPKO Health, Inc.
Not applicableCompleted100Dec 22, 2020Registry ↗
Mar 23, 2021Efficacy and Safety of a Intra-articular Injection, ENKO1, in Patients With Symptomatic Knee Osteoa…
NCT03762408 · Osteoarthritis, Knee
ENKO 1, Durolane
OPK
OPKO Health, Inc.
Not applicableCompleted175May 29, 2020Registry ↗
Apr 28, 2020A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presen…
NCT03810664 · Healthy Male Volunteers
Somatrogon
OPK
OPKO Health, Inc.
Phase 1Completed49Apr 19, 2019Registry ↗
Jan 23, 2020Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
NCT01592500 · Pediatric Growth Hormone Deficiency
MOD-4023, Somatropin
OPK
OPKO Health, Inc.
Phase 2Completed56Jul 2015Registry ↗
Nov 4, 2019A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia
NCT01791725 · Down Syndrome
ELND005, Placebo
OPK
OPKO Health, Inc.
Phase 2Completed23Jun 2014Registry ↗
Nov 1, 2019ELND005 in Patients With Mild to Moderate Alzheimer's Disease
NCT00568776 · Alzheimer Disease
Placebo Control, ELND005
OPK
OPKO Health, Inc.
Phase 2Completed353May 2010Registry ↗
Oct 21, 2019A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheime…
NCT01766336 · Alzheimer's Disease
Group 1 ELND005, Group 2 ELND005
OPK
OPKO Health, Inc.
Phase 2Terminated296Aug 2015Registry ↗
Oct 21, 2019Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Dis…
NCT01735630 · Alzheimer's Disease
ELND005, Placebo
OPK
OPKO Health, Inc.
Phase 2Completed350May 2015Registry ↗
Oct 21, 2019Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder
NCT01674010 · Bipolar 1 Disorder
ELND005, Lamotrigine
OPK
OPKO Health, Inc.
Phase 2Terminated309Jun 2014Registry ↗
Oct 21, 2019ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
NCT00934050 · Alzheimer's Disease
ELND005 (scyllo-inositol)
OPK
OPKO Health, Inc.
Phase 2Completed103Jun 2011Registry ↗
Oct 18, 2019A Study in Type 2 Diabetic Patients With Repeated Doses of E1 in Combination With G1
NCT00239187 · Type 2 Diabetes
E1 and G1
OPK
OPKO Health, Inc.
Phase 1Completed30—Registry ↗
Oct 18, 2019A Study in Type 1 Diabetic Patients With Repeated Doses of E1 in Combination With G1
NCT00239148 · Type 1 Diabetes
E1 and G1
OPK
OPKO Health, Inc.
Phase 1Completed20—Registry ↗
Oct 18, 2019Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavi…
NCT00230854 · Chronic Hepatitis C, Hepatitis, Viral, Human
EMZ702
OPK
OPKO Health, Inc.
Phase 1Completed28—Registry ↗
Oct 17, 20194Kscore Using Serum Stored Uncentrifuged
NCT04130776 · Prostate Cancer
Measurement of four prostate-specific kallikreins for the 4…
OPK
OPKO Health, Inc.
—Completed64Mar 27, 2018Registry ↗
Oct 8, 2019MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA)
NCT01225666 · Adult Growth Hormone Deficiency
MOD-4023, MOD-4023
OPK
OPKO Health, Inc.
Phase 2Completed52Jul 2011Registry ↗
Sep 30, 2019Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects…
NCT03660800 · Vitamin D Insufficiency, Secondary Hyperparathyroidism
CTAP101 Capsules
OPK
OPKO Health, Inc.
Phase 1Completed67Oct 24, 2018Registry ↗
Sep 30, 2019A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male
NCT02919800 · Hemophilia A or B With Inhibitors
MOD-5014, MOD-5014 Placebo
OPK
OPKO Health, Inc.
Phase 1Completed32Feb 21, 2018Registry ↗
Sep 30, 2019A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subje…
NCT02692781 · Obesity
MOD-6031, Placebo control
OPK
OPKO Health, Inc.
Phase 1Completed32Dec 15, 2016Registry ↗
Sep 30, 2019Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023)…
NCT02418767 · Growth Hormone Deficiency
MOD-4023, Placebo
OPK
OPKO Health, Inc.
Phase 1Completed42Mar 2015Registry ↗
Sep 30, 2019MOD-4023 Study in Healthy Male Volunteers
NCT01060722 · Healthy
MOD-4023 (long lasting hGH), Placebo
OPK
OPKO Health, Inc.
Phase 1Completed24Jan 2010Registry ↗
Sep 27, 2019Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Deno…
NCT02274623 · Breast Cancer, Prostate Cancer
CTAP101 Capsules
OPK
OPKO Health, Inc.
Phase 1Completed33Feb 27, 2017Registry ↗
Nov 30, 2017Efficacy and Tolerability of a Nutritional Supplement, Plactive Progen, in ACL Reconstruction
NCT03355651 · ACL Reconstruction
PROGEN
OPK
OPKO Health, Inc.
Not applicableCompleted80Feb 1, 2017Registry ↗
Sep 29, 2016Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002
NCT02282813 · Chronic Kidney Disease, Hyperparathyroidism, Secondary
CTAP101 Capsules, Calcitriol
OPK
OPKO Health, Inc.
Phase 3Completed298May 2015Registry ↗
Aug 25, 2016Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroid…
NCT01219855 · Chronic Kidney Disease, Secondary Hyperparathyroidism
Cohort 1 CTAP101 Capsules- 60µg, Cohort 1 CTAP101 Capsules…
OPK
OPKO Health, Inc.
Phase 2/3Completed78Nov 2011Registry ↗
Mar 6, 2015Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CA…
NCT00557791 · Age Related Macular Degeneration
Bevasiranib, ranibizumab
OPK
OPKO Health, Inc.
Phase 3Withdrawn0Jul 2011Registry ↗

40 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:51 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances